CH Robinson Stock Slides as Rising Costs, Cash Flow Concerns Overshadow Earnings Beat

Shares of C.H. Robinson Worldwide (NASDAQ: CHRW) fell 4.3% in pre-market trading after the company's third-quarter earnings report, which beat headline estimates, revealed underlying cost pressures and a significant drop in cash flow that concerned investors.

Earnings Details Reveal Pressure Points

The logistics and freight brokerage firm reported adjusted earnings per share of $1.80, which was $0.05 ahead of the consensus analyst estimate of $1.75. Revenue for the quarter reached $5.36 billion, a year-over-year increase of 29.5% that also surpassed the expected $4.92 billion.

However, the strong top-line performance was overshadowed by rising costs and weakening cash generation. Key points of concern for the market include:

• Operating expenses surged 10.6% to $536.6 million, driven by higher incentive compensation, claims expenses, and a $12.2 million impairment charge related to a lease in Kansas City.
• Cash from operations plummeted to $124.1 million, a sharp decrease from the $275.4 million generated in the same period last year. The company attributed the decline primarily to unfavorable changes in working capital caused by higher transportation rates.

Ad

Acquisition Uncertainty and Analyst Caution

The earnings release comes amid persistent investor uncertainty surrounding C.H. Robinson's recently announced plan to acquire RXO, the third-largest freight broker in North America. While management anticipates the deal will generate $300 million in annual synergies within two years, concerns about integration risk and the financial burden of the transaction have tempered market sentiment.

Reflecting this caution, several analyst firms including Raymond James, Deutsche Bank, and BMO Capital cut their price targets on CHRW shares this month following the October 5 acquisition announcement. The stock's pre-market decline to $137.48 suggests that investors are prioritizing cleaner operational execution and clarity on the RXO deal before rewarding the company's growth.